- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
N4.9 million US dollars in funding each year to find a cure for HIV
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
4.9 million US dollars in funding each year to find a cure for HIV.
A team led by Dan Barouch, Professor of Medicine at the Royal College of Medicine William Bosworth Castle and Director of the Virology and Vaccine Research Center at Beth Israel Deaconess Medical Center, will receive US$4.9 million annually for the next five years to find a cure for HIV .
He is one of the 10 principal researchers who won the 2021 National Institutes of Health Martin Delaney Collaborative Research Award, which aims to coordinate complex research and guide the next generation by bringing together research partners from academia, government, private sector, and communities HIV researchers accelerate research on the cure of human immunodeficiency virus/HIV/AIDS/AIDS.
Barouch is a leader in the field of HIV research. He and his colleagues will focus on the virus host-HIV-infected immune cells. Despite receiving antiretroviral therapy (ART), they are still dormant. If ART is interrupted , They will be reactivated-and develop new immunological strategies against the host.
More than 35 million people worldwide are infected with HIV, with nearly 2 million new cases every year. HIV is still a major global epidemic.
Barouch said: “The latent virus pool is a key obstacle to the development of treatments for HIV-1 infection.” He added: “Our overall assumption is that multiple immune strategies need to be explored and combined to achieve long-term, art-free virological control or Completely eradicate the virus. We are very grateful for this grant and very excited to see that with this long-term source of support, we can make progress.”
Dan Barouch. Courtesy Beth Israel Deaconess
The National Institutes of Health’s collaborative research project was launched in 2010 in memory of the late HIV/AIDS activist Martin Delaney, who served on the National Institute of Allergy and Infectious Diseases and AIDS Research Advisory Committee of the National Institutes of Health.
The new awards will focus on three key areas: basic research on HIV host and post-treatment control; strategies for sustained control of viral rebound; and methods to reduce, eradicate, or inactivate latent viruses.
Mark Zedel, Director of the Medical Department of Beth Israel Deaconess Hospital, said: “Dr. Barouch has performed elegant and innovative scientific research to improve our understanding of HIV.”.
His innovations include the development of novel and efficient adenovirus vectors, and the development and application of highly relevant animal models to test the efficacy of candidate vaccines. We look forward to seeing his future contributions to HIV research with this generous support. “
Barouch is a member of the Massachusetts Institute of Technology and the Harvard Lagon Institute and has a good track record in developing new vaccines and treatments for viruses of global importance. Barouch is also the co-leader of the Vaccine Working Group of the Massachusetts Institute of Pathogen Preparedness.
In addition to cooperating with Johnson & Johnson to develop a single-dose COVID-19 vaccine, Barouch and his colleagues developed the first Zika virus vaccine and the first global mosaic virus type 1 vaccine in 2016. They are currently in phase 3 clinical trials. The experimental stage.
Gyongyi Szabo, Chief Academic Officer of Beth Israel Deaconess and Beth Israel Lahey Health, said: “At BIDMC, our scientists are committed to transforming innovation and scientific discoveries into clinical practice. An immeasurable contribution.
(source:internet, reference only)